

16 May 2008

REGEN THERAPEUTICS PLC
(“ReGen” or the “Company”; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation (iii):

Andrew Clement Wilson

4. Full name of shareholder(s) (if difference from 3):

As above

5. Date of the transaction and date on which the threshold is crossed or reached (v):

14 May 2008

6. Date on which issued notified:

16 May 2008

7. Threshold(s) that is/are crossed or reached:

12%

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code	GB00B28XMY25
Situation Previous to the triggering transaction (vi) –	
Number of Shares	1,372,000
Number of Voting Rights (viii)	1,372,000
Resulting situation after the triggering transaction (viii) –	
Number of Shares	1,387,000
Number of Voting Rights – Direct (x)	1,387,000
Number of Voting Rights – Indirect (xi)	N/A
% of voting rights – Direct	12.08
% of voting rights – Indirect	N/A

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument	N/A
Expiration date (xiii)	N/A
Exercise/Conversion Period/Date (xiv)	N/A
Number of voting rights that may be acquired if the instrument is exercised/converted	N/A
% of voting rights	N/A
Total (A+B)	
Number of voting rights	1,387,000
% of voting rights	12.08

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

Shares are held in own name

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A
13. Additional information:	N/A
14. Contact name:	N/A
15. Contact telephone number:	N/A

For further information:

Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920

Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396